Godavari Biorefineries Q1 FY27: consolidated loss widens to ₹19.3 Cr on sugar drag

Godavari Biorefineries posted a consolidated net loss of ₹19.32 Cr on revenue of ₹557.88 Cr for Q1 FY27 (quarter ended June 30, 2026) — revenue grew 4.6% YoY but was down 1.1% QoQ, while the loss widened from ₹16.02 Cr a year ago (+21% wider) and reversed from a ₹52.88 Cr profit in the seasonally strong Q4 FY26. Standalone results were weaker still, with a ₹21.27 Cr loss and EPS of -₹4.16 versus the consolidated -₹3.78, meaning subsidiaries contributed modestly positive earnings this quarter. No formal Street estimates for this print turned up in a search — Godavari Biorefineries carries sparse analyst coverage as a small-cap — so the result cannot be benchmarked against consensus.

The drag was almost entirely the sugar segment, which swung to a ₹16.04 Cr operating loss from a ₹13.88 Cr loss a year ago and a ₹59.24 Cr profit in the peak-crushing Q4 — consistent with the company's own note that some segments are seasonal and Q1 results aren't representative of annual performance. Consolidated NPM turned negative at -3.45% (vs +9.28% in Q4, -3.00% a year ago) and consolidated operating profit (segment basis) swung to a ₹11.92 Cr loss from profits in both comparison quarters. Bio-based chemicals was the one segment that delivered: revenue rose 19.5% YoY to ₹168.67 Cr and segment profit nearly doubled YoY to ₹15.83 Cr, in line with management's prior guidance on debottlenecking gains. Distillery, by contrast, swung to a ₹1.77 Cr operating loss from an ₹8.15 Cr profit a year ago, despite the company commissioning its new 200 KLPD grain-based distillery at Sameerwadi on June 29, 2026 (lifting total ethanol capacity to 800 KLPD) — the commissioning came too late in the quarter to register any contribution.

The stock went into the print at ₹268, up 1.1% over the past month of trading.

Against the confident Q4 FY26 concall commentary — which flagged a stronger bio-chemicals outlook from debottlenecking "starting this quarter" and framed the incoming ethanol capacity as a performance boost — the quarter is a mixed read: bio-chemicals delivered as guided, but the consolidated bottom line still posted a wider YoY loss, so guidance is missed at the aggregate level. There were no exceptional items in either the current or year-ago quarter, so the YoY comparison is like-for-like with no adjustment needed. Management's own press release framed the quarter around the distillery commissioning and capacity milestone, describing it as strengthening the platform's resilience and feedstock flexibility, rather than addressing the wider loss directly — the P&L doesn't yet show that payoff.